Available now: Building an Investable IP Portfolio Whitepaper
​

AstraZeneca patent revoked for obviousness

No items found.
​
March 29, 2012
#
Life
Table of contents
  • Toc Heading
  • Toc Heading

In a decision on 22 March in Teva and ors v AstraZeneca concerning a patent on a sustained release formulation of an anti-psychotic drug, Mr Justice Arnold revoked the patent due to obviousness.

In his IPKat blog, Darren Smyth draws comparisons between this decision and that of Actavis v Novartis, which involved a patent concerning a sustained release formulation of fluvastatin that was held to be obvious.

Recent Case Reports

See all Case Reports

Replacement parts and the value of asserting a narrower claim combination
17 July 2026
The UPC's Düsseldorf Local Division found that Wessper's cartridges indirectly infringed Brita's patent, and that a narrower claim combination can turn a consumable into an essential element.
​
Late Applications for Provisional Measures Refused for Lack of Urgency
14 July 2026
In Ericsson v ASUSTeK, the Milan Local Division refused a provisional measures application filed 21 months into the case, finding continuing infringement and rising losses alone do not establish urgency.
​
UPC revokes provisional injunction on motorbike helmet intercoms system
29 June 2026
The UPC Local Division Milan revoked Cardo's provisional injunction against Reso, ruling its helmet intercom products fall outside the scope of EP4240194, neither literally nor by equivalence.
​